BDNF and Huntington disease: Reduced levels of acetylated tubulin have also been observed in the brains of patients affected by Huntington disease (HD), and the pharmacological treatment of mouse striatal cells derived from transgenic HD mice with compounds that increment tubulin acetylation stimulates MT-dependent transport of BDNF and prevents the alterations observed in HD mutant cells [131].